Deliverable. Flexible. Visible. Compatible.
Deliverable. Flexible. Visible. Compatible.
START
Sintra Medical was founded in 2019 with the goal of introducing its patented technology for the minimally invasive treatment of peripheral artery disease (PAD) to the global market.
RESULTS
Sintra Medical’s patented technology is in development and is not approved for sale or use in the United States and or international markets.
NEXT STEPS
The Sintra Medical Team is committed to making its technology commercially available to patients and physicians around the world, and to develop new applications for its technology platform.
PATENTS
The Sintra Medical technology is protected by an IP portfolio of several patents issued and/or published in all relevant geographies.